To include your compound in the COVID-19 Resource Center, submit it here.

Sunesis starts Ph Ib/II of SNS-062 for B cell malignancies

Sunesis Pharmaceuticals Inc. (NASDAQ:SNSS) began an open-label, U.S. Phase Ib/II trial of SNS-062 to treat chronic lymphocytic leukemia

Read the full 187 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE